Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-cash Items (2017 - 2025)

Protagonist Therapeutics' Non-cash Items history spans 8 years, with the latest figure at $501.3 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 227.86% year-over-year to $501.3 million; the TTM value through Dec 2025 reached $501.3 million, up 227.86%, while the annual FY2025 figure was $501.3 million, 227.86% up from the prior year.
  • Non-cash Items for Q4 2025 was $501.3 million at Protagonist Therapeutics, up from $152.9 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $501.3 million in Q4 2025 and bottomed at $3.0 million in Q2 2021.
  • The 5-year median for Non-cash Items is $32.0 million (2023), against an average of $83.0 million.
  • The largest annual shift saw Non-cash Items skyrocketed 2913.64% in 2021 before it crashed 94.95% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $102.7 million in 2021, then tumbled by 96.31% to $3.8 million in 2022, then skyrocketed by 1485.33% to $60.0 million in 2023, then surged by 154.83% to $152.9 million in 2024, then skyrocketed by 227.86% to $501.3 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Non-cash Items are $501.3 million (Q4 2025), $152.9 million (Q4 2024), and $60.0 million (Q4 2023).